** Drugmaker Incyte's INCY.O shares rise 4.4% to $79.69
** INCY said on Sunday its experimental blood cancer treatment showed it could target and remove cancer cells while leaving healthy cells intact, potentially restoring normal blood production
** The therapy treats a group of blood disorders where a specific gene mutation causes blood cells to multiply uncontrollably
** 86% of patients on higher doses of the experimental therapy showed significant improvement in blood cell counts, with most (82%) achieving complete normalization of their previously elevated platelet levels
** INCY plans to meet with regulators and aims to start late-stage testing by early 2026
** Including session's moves, INCY stock down up 0.9% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。